News

The Hill2mon
FDA approves first new UTI drug in decades
The drug is effective against UTIs caused by E. coli, klebsiella, Citrobacter freundii, Staphylococcus saprophyticus and Enterococcus faecalis. The most common side effects reported from using the ...
Healio3mon
FDA approves Emblaveo for complicated intra-abdominal infections
Citrobacter freundii complex and Serratia marcescens, for which there are few or no alternative treatment options. "The continued evolution of antimicrobial resistance among gram-negative bacteria ...
pharmaphorum5d
Merck gets FDA nod for new antibiotic, but says use with care
The injectable antibiotic can also used for cIAI caused by all those organisms, plus seven Bacteroides strains, Citrobacter freundii, Fusobacterium nucleatum, Klebsiella oxytoca and ...
New Atlas1mon
First new stroke and UTI drugs in 30 years get FDA approval
Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. More than half of all women will contract this kind of UTI in their lifetime, and almost a third will battle ...
FiercePharma2mon
GSK ushers in new UTI antibiotic with FDA nod for first-in-class Blujepa
coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus or Enterococcus faecalis in women 12 years of age and older. These types of UTIs are the most common ...
Renal & Urology News3mon
Emblaveo Approved for Intra-Abdominal Infections in Patients With Limited Options
Citrobacter freundii complex, and Serratia marcescens. Emblaveo is a fixed-dose intravenous (IV) treatment that combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.
FiercePharma3mon
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex and Serratia marcescens. These infections can be difficult to treat as the bacteria ...